AI biotech company Owkin has teamed up with AstraZeneca to develop an AI-based tool for identifying gBRCA mutations in breast cancer patients. The tool will analyze digitized pathology slides, aiming to increase access to BRCA testing, which plays a critical role in determining breast and ovarian cancer risk. By streamlining this diagnostic process, the tool is expected to benefit many patients who might otherwise be overlooked for testing.
Owkin will leverage data from over 6,500 pathology slides to train the AI tool, in collaboration with French institutions Gustave Roussy and The Centre Léon Bérard. The initiative seeks to speed up BRCA testing and ensure more personalized treatment decisions. As BRCA mutations significantly influence treatment strategies, the ability to identify them more efficiently could lead to improved outcomes for many patients.
This partnership highlights the growing role of AI in precision medicine. By offering advanced screening tools and enhancing early detection, Owkin and AstraZeneca are contributing to a broader trend in healthcare, where technology aids in better clinical decision-making and tailored therapies for high-risk patients.
Click here to read the original news story.